🔴 GT Biopharma is trading 11.2% down today after $7.45 million convertible financing raises dilution concerns

GT Biopharma is trading 11.2% down now at $7.99 as investors continue digesting its September 14, 2026, private placement of $7.45 million in securities, increasing potential dilution.

• The financing included Series M convertible preferred stock and warrants convertible at $6.10 per share.
• Warrants equal to conversion shares and substantial greenshoe rights add to potential dilution.
• The financing followed a 22.61% decline on September 15, 2026.